Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826650 | 0.82 | SYK (0.55) | SYKMAP4K4ABL1LCKFYN | |
| SCHEMBL17037408 | 0.81 | MAP3K12 (0.47) | SYKMAP3K12MAP4K4ABL1LCK | |
| SCHEMBL17026074 | 0.81 | SYK (0.49) | SYKMAP3K12MAP4K4ABL1LCK | |
| SCHEMBL13726219 | 0.78 | TRPV4 (0.44) | SYKMAP3K12MAP4K4ABL1LCK | |
| SCHEMBL16820071 | 0.77 | SYK (0.44) | SYKMAP4K4ABL1LCKFYN | |
| SCHEMBL13826651 | 0.75 | SYK (0.40) | SYKMAP3K12MAPK8MAPK9 | |
| SCHEMBL15819661 | 0.75 | SYK (0.53) | SYKMAP3K12 | |
| SCHEMBL15634682 | 0.75 | SYK (0.45) | SYKMAP3K12MAP4K4ABL1LCK | |
| SCHEMBL16840109 | 0.75 | SYK (0.52) | SYKMAP3K12MAP4K4ABL1LCK | |
| SCHEMBL13726067 | 0.74 | SYK (0.62) | SYKMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934525-B1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2934525-B1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2863914-B1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2863913-B1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2900665-B1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9598405-B2 | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598405-B2 | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598405-B2 | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2707357-B1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| EP-2863913-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
| WO-2014100314-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100314-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
| WO-2013192128-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | disclosed |
| WO-2012154518-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885MAP3K12 143/4885MAP4K4 363/4885 |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885MAP3K12 152/4885MAP4K4 385/4885 |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885MAP3K12 134/4885MAP4K4 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.